Skip to main content

Table 2 Risk indices (n = 780)

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

  Group A
Bridging
n = 111
Group B
VKA
n = 318
Group C
DOAC
n = 351
p-value
A-B
p-value
A-C
p-value
B-C
CHA2DS2VASc     0.441 0.176 0.431
 0 10 (9.0) 33 (10.4) 57 (16.2)    
 1 34 (30.6) 112 (35.2) 121 (34.5)    
 2 38 (34.2) 82 (25.8) 90 (25.6)    
 3 16 (14.4) 57 (17.9) 51 (14.5)    
 4 11 (9.9) 24 (7.5) 22 (6.3)    
 5 1 (0.9) 9 (2.8) 9 (2.6)    
 6 1 (0.9) 1 (0.3) 1 (0.3)    
HAS-BLED     0.903 0.006 0.001
 0 14 (12.6) 40 (12.6) 85 (24.2)    
 1 47 (42.3) 117 (36.8) 156 (44.4)    
 2 33 (29.7) 109 (34.3) 80 (22.8)    
 3 14 (12.6) 43 (13.5) 29 (8.3)    
 4 3 (2.7) 8 (2.5) 1 (0.3)    
 5 0 (0.0) 1 (0.3) 0 (0.0)    
  1. Legend: Bridging interrupted vitamin-K-antagonist, CHA 2 DS 2 VASc cardiac failure or dysfunction, hypertension, age ≥ 75 [doubled], diabetes, stroke [doubled]-vascular disease, age 65–74, sex category [female]) score, DOAC uninterrupted non-vitamin-K anticoagulants, HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (> 65 years), drugs/alcohol concomitantly, VKA uninterrupted vitamin-K-antagonist